EverSource Wealth Advisors’s Cytek Biosciences CTKB Stock Holding History

EverSource Wealth Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.41K	Sell	1,221 -600	-33%	-$2.56K	﹤0.01%	3248
2026 Q1	$7.96K	Buy	1,821 +242	+15%	+$1.14K	﹤0.01%	3040
2025 Q4	$7.97K	Sell	1,579 -206	-12%	-$957	﹤0.01%	2916
2025 Q3	$6.19K	Buy	1,785 +5	+0.3%	+$19	﹤0.01%	3058
2025 Q2	$6.05K	Buy	1,780 +1,246	+233%	+$4.15K	﹤0.01%	3069
2025 Q1	$2.14K	Buy	534 +449	+528%	+$2.33K	﹤0.01%	2899
2024 Q4	$552	Buy	+85	New	+$506	﹤0.01%	3152
2024 Q3	–	Sell	-158	Closed	-$1.06K	–	3051
2024 Q2	$1.06K	Hold	158	–	–	﹤0.01%	2728
2024 Q1	$950	Buy	158 +26	+20%	+$206	﹤0.01%	2602
2023 Q4	$1.2K	Buy	+132	New	+$831	﹤0.01%	2338
2023 Q3	–	Sell	-69	Closed	-$589	–	2534
2023 Q2	$589	Buy	+69	New	+$619	﹤0.01%	2317

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EverSource Wealth Advisors's CTKB Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Cytek Biosciences (CTKB) stake by 33% in Q2 2026, selling an estimated $2.56K and leaving 1,221 shares worth $5.41K. The position accounts for ﹤0.01% of the portfolio, ranked #3248.

EverSource Wealth Advisors first reported a position in CTKB in Q2 2023 and has held it in 11 quarters since. The position peaked at $7.97K in Q4 2025. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

EverSource Wealth Advisors held 1,221 shares of Cytek Biosciences worth $5.41K as of Q2 2026.
EverSource Wealth Advisors sold 600 Cytek Biosciences shares in Q2 2026, an estimated $2.56K.
Cytek Biosciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3248 holding.
EverSource Wealth Advisors first reported a position in Cytek Biosciences in Q2 2023 and has held it in 11 quarters since.
EverSource Wealth Advisors's Cytek Biosciences position peaked at $7.97K in Q4 2025.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.